To include your compound in the COVID-19 Resource Center, submit it here.

CDER presents its Avastin case

Members of the Oncologic Drugs Advisory Committee (ODAC) on Tuesday seemed to agree with the opinion of FDA's CDER that data do not support

Read the full 247 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE